八种血浆Aβ42/40检测方法在阿尔茨海默病中的头对头比较
该研究在BioFINDER队列(182名认知正常者与104名轻度认知障碍患者)及ADNI验证队列中,头对头比较了8种血浆Aβ42/40检测方法识别脑Aβ病理(CSF或PET)的判别准确性。结果显示,部分质谱法(尤其IP-MS-WashU)优于多数免疫分析法,而IP-MS-WashU与IP-MS-Shim之间无显著差异。
要点
- IP-MS-WashU法识别异常CSF Aβ42/40的AUC为0.86,显著高于LC-MS-Arc、IA-Elc、IA-EI和IA-N4PE(AUC 0.69-0.78)。
核心结论
- 在BioFINDER和ADNI两个独立队列中,部分质谱法检测血浆Aβ42/40识别脑Aβ病理的判别准确性优于多数免疫分析法。
研究设计与样本
- BioFINDER队列纳入182名认知正常者和104名轻度认知障碍患者,来自瑞典3家医院,2010至2014年入组,接受Aβ-PET及CSF和血浆采集。
- 部分检测在200名或227名参与者子队列中进行;ADNI验证队列纳入122名参与者(51名认知正常、51名轻度认知障碍、20名AD痴呆)。
主要发现
- 以Aβ-PET为结局时结果相似;IP-MS-WashU和IP-MS-Shim与CSF Aβ42/40的相关系数最高(r范围0.56-0.65)。
- ADNI队列重复了BioFINDER结果:IP-MS-WashU显著优于IP-MS-UGOT、IA-Elc、IA-N4PE和IA-Quan,但与IP-MS-Shim无显著差异。
临床怎么用
- 临床选用血浆Aβ42/40检测时,应优先考虑质谱法(如IP-MS-WashU或IP-MS-Shim),其判别脑Aβ病理的准确性高于多数免疫分析法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Blood-based tests for brain amyloid-β (Aβ) pathology are needed for widespread implementation of Alzheimer disease (AD) biomarkers in clinical care and to facilitate patient screening and monitoring of treatment responses in clinical trials. OBJECTIVE: To compare the performance of plasma Aβ42/40 measured using 8 different Aβ assays when detecting abnormal brain Aβ status in patients with early AD. DESIGN, SETTING, AND PARTICIPANTS: This study included 182 cognitively unimpaired participants and 104 patients with mild cognitive impairment from the BioFINDER cohort who were enrolled at 3 different hospitals in Sweden and underwent Aβ positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) and plasma collection from 2010 to 2014. Plasma Aβ42/40 was measured using an immunoprecipitation-coupled mass spectrometry developed at Washington University (IP-MS-WashU), antibody-free liquid chromatography MS developed by Araclon (LC-MS-Arc), and immunoassays from Roche Diagnostics (IA-Elc); Euroimmun (IA-EI); and Amsterdam University Medical Center, ADx Neurosciences, and Quanterix (IA-N4PE). Plasma Aβ42/40 was also measured using an IP-MS-based method from Shimadzu in 200 participants (IP-MS-Shim) and an IP-MS-based method from the University of Gothenburg (IP-MS-UGOT) and another immunoassay from Quanterix (IA-Quan) among 227 participants. For validation, 122 participants (51 cognitively normal, 51 with mild cognitive impairment, and 20 with AD dementia) were included from the Alzheimer Disease Neuroimaging Initiative who underwent Aβ-PET and plasma Aβ assessments using IP-MS-WashU, IP-MS-Shim, IP-MS-UGOT, IA-Elc, IA-N4PE, and IA-Quan assays. MAIN OUTCOMES AND MEASURES: Discriminative accuracy of plasma Aβ42/40 quantified using 8 different assays for abnormal CSF Aβ42/40 and Aβ-PET status. RESULTS: A total of 408 participants were included in this study. In the BioFINDER cohort, the mean (SD) age was 71.6 (5.6) years and 49.3% of the cohort were women. When identifying participants with abnormal CSF Aβ42/40 in the whole cohort, plasma IP-MS-WashU Aβ42/40 showed significantly higher accuracy (area under the receiver operating characteristic curve [AUC], 0.86; 95% CI, 0.81-0.90) than LC-MS-Arc Aβ42/40, IA-Elc Aβ42/40, IA-EI Aβ42/40, and IA-N4PE Aβ42/40 (AUC range, 0.69-0.78; P < .05). Plasma IP-MS-WashU Aβ42/40 performed significantly better than IP-MS-UGOT Aβ42/40 and IA-Quan Aβ42/40 (AUC, 0.84 vs 0.68 and 0.64, respectively; P < .001), while there was no difference in the AUCs between IP-MS-WashU Aβ42/40 and IP-MS-Shim Aβ42/40 (0.87 vs 0.83; P = .16) in the 2 subcohorts where these biomarkers were available. The results were similar when using Aβ-PET as outcome. Plasma IPMS-WashU Aβ42/40 and IPMS-Shim Aβ42/40 showed highest coefficients for correlations with CSF Aβ42/40 (r range, 0.56-0.65). The BioFINDER results were replicated in the Alzheimer Disease Neuroimaging Initiative cohort (mean [SD] age, 72.4 [5.4] years; 43.4% women), where the IP-MS-WashU assay performed significantly better than the IP-MS-UGOT, IA-Elc, IA-N4PE, and IA-Quan assays but not the IP-MS-Shim assay. CONCLUSIONS AND RELEVANCE: The results from 2 independent cohorts indicate that certain MS-based methods performed better than most of the immunoassays for plasma Aβ42/40 when detecting brain Aβ pathology.
引用
- Janelidze S, Teunissen CE, Zetterberg H, et al. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. JAMA Neurol. 2021. PMID: 34542571. doi:10.1001/jamaneurol.2021.3180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。